CytomX Therapeutics (CTMX) Total Liabilities (2014 - 2026)

CytomX Therapeutics has reported Total Liabilities for 13 years, with the latest figure at $39.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 46.34% year-over-year to $39.4 million; the trailing twelve-month figure through Mar 2026 stood at $39.4 million (down 46.34% YoY), and the FY2025 full-year result was $52.6 million, down 56.56% from the prior year.
• Total Liabilities for Q1 2026 stood at $39.4 million, down from $52.6 million in the prior quarter.
• The five-year high for Total Liabilities was $346.6 million in Q4 2022, with the low at $39.4 million in Q1 2026.
• Historically, Total Liabilities has averaged $199.6 million across 5 years, with a median of $216.4 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities grew 1.99% — and 2025, when it plunged 71.04%.
• CytomX Therapeutics' Total Liabilities stood at $346.6 million in 2022, then dropped by 28.1% to $249.2 million in 2023, then tumbled by 51.46% to $121.0 million in 2024, then sank by 56.56% to $52.6 million in 2025, then fell by 25.01% to $39.4 million in 2026.
• The last three Total Liabilities figures came in at $39.4 million (Q1 2026), $52.6 million (Q4 2025), and $50.9 million (Q3 2025), per Business Quant data.